

1 **Durability of ChAdOx1 nCov-19 (AZD1222) vaccination in people living with**
2 **HIV - responses to SARS-CoV-2, variants of concern and circulating**
3 **coronaviruses**

4 Ane Ogbe*¹, Mathew Pace*¹, Mustapha Bittaye*⁴, Timothy Tipoe¹, Sandra Adele¹,
5 Jasmini Alagaratnam^{6,7}, Parvinder K Aley⁸, M. Azim Ansari¹, Anna Bara⁹, Samantha
6 Broadhead¹³, Anthony Brown¹, Helen Brown¹, Federica Cappuccini⁴, Paola
7 Cinardo¹⁰, Wanwisa Dejnirattisai¹¹, Katie J. Ewer⁴, Henry Fok¹⁰, Pedro M. Folegatti⁴,
8 Jamie Fowler⁴, Leila Godfrey⁴, Anna L. Goodman¹⁰, Bethany Jackson¹⁰, Daniel
9 Jenkin⁴, Mathew Jones¹, Stephanie Longet^{11,12}, Rebecca Makinson⁴, Natalie G.
10 Marchevsky⁸, Moncy Mathew¹⁰, Andrea Mazzella¹⁰, Yama F. Mujadidi⁸, Lucia
11 Parolini¹, Claire Petersen^{6,7}, Emma Plested⁸, Katrina M. Pollock⁹, Thurkka
12 Rajeswaran¹⁰ Maheshi N. Ramasamy⁸, Sarah Rhead⁸, Hannah Robinson⁸, Nicola
13 Robinson^{1,3}, Helen Sanders⁴, Sonia Serrano¹³, Helen Stockmann⁷, Tom Tipton^{11,12},
14 Anele Waters¹⁰, Panagiota Zacharopoulou¹, Eleanor Barnes^{1,2,3,4}, Susanna
15 Dunachie^{1,2,14,15}, Philip Goulder^{1,2,5}, Paul Klenerman^{1,2,3}, Gavin R. Screaton¹¹, Alan
16 Winston^{6,7}, Adrian V. S. Hill⁴, Sarah C. Gilbert⁴, Miles Carroll^{11,12}, Andrew J
17 Pollard*^{3,8}, Sarah Fidler*^{6,7}, Julie Fox^{10,13*}, Teresa Lambe*⁴, John Frater*^{1,2,3}

18
19 ¹Peter Medawar Building for Pathogen Research, Nuffield Dept of Clinical Medicine,
20 University of Oxford, Oxford, UK

21 ²Oxford University Hospitals NHS Foundation Trust, Oxford, UK

22 ³NIHR Oxford Biomedical Research Centre, Oxford, UK

23 ⁴The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford,
24 UK

25 ⁵Department of Paediatrics, University of Oxford, Oxford, UK

26 ⁶Department of Infectious Disease, Faculty of Medicine, Imperial College London,
27 London, UK

28 ⁷Department of HIV Medicine, St Mary's Hospital, Imperial College Healthcare NHS
29 Trust, London, UK

30 ⁸Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.

31 ⁹NIHR Imperial Clinical Research Facility and NIHR Imperial Biomedical Research
32 Centre, London, UK

33 ¹⁰Department of Infection, Harrison Wing and NIHR Clinical Research Facility, Guys
34 and St Thomas' NHS Trust, London, UK

35 ¹¹Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University
36 of Oxford, Oxford, UK

37 ¹²Public Health England, Porton Down, UK.

38 ¹³NIHR Guy's and St Thomas' Biomedical Research Centre

39 ¹⁴Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine,
40 University of Oxford, Oxford, UK

41 ¹⁵Mahidol-Oxford Tropical Medicine Research Unit, Mahidol University, Bangkok,
42 Thailand

43
44 *Contributed equally

45
46
47 **Correspondence to:** ~~medRxiv preprint doi: <https://doi.org/10.1101/2021.09.28.21264207>; this version posted September 29, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/) .~~ research that has not been certified by peer review and should not be used to guide clinical practice.

48 John Frater, Peter Medawar Building for Pathogen Research, Nuffield Dept of
49 Clinical Medicine, University of Oxford, Oxford, UK, OX1 3SY;
50 john.frater@ndm.ox.ac.uk
51 Ane Ogbe, Peter Medawar Building for Pathogen Research, Nuffield Dept of Clinical
52 Medicine, University of Oxford, Oxford, UK, OX1 3SY; ane.ogbe@ndm.ox.ac.uk
53

54 **Author Contributions**

55 JFr, Ao, SF, JFo, TL. AJP, SCG, AVSH, AA, KJE were involved in conceptualisation,
56 data curation, funding acquisition, supervision, methodology, writing and reviewing the
57 manuscript. AO, MP, SA, EA, MA, AA, AB, HB, MJ, LP, NR, TT, PZ were involved with
58 sample methodology and preparation, assay performance, data curation (CTV
59 assays), data analysis and writing and reviewing the manuscript. EB, SD, PG, PK were
60 involved in supervision, data curation, investigation, methodology and writing and
61 reviewing the manuscript. SL, ToT, MC oversaw MSD and ACE-inhibition assays; JA,
62 AB, CP, KMP, HS, AW, SF managed study recruitment at Imperial; PC, AM, TR, BJ,
63 MM, SB, HK, ALG, SS, AW, JFo managed study recruitment at Guy's; WD, GRS were
64 involved in data curation (neutralisation), formal analysis, methodology and writing and
65 reviewing the manuscript. AB, JA, CP, KP, HS, AW, SF were involved in data curation,
66 methodology, project administration, supervision, investigation and writing and
67 reviewing the manuscript. PA was involved in project administration. MB, FC, PF,
68 JFow, DJ, RM, TL were involved in data curation, formal analysis, investigation,
69 methodology and writing and reviewing the manuscript. SB, HF, ALG, SS, AW, JFox
70 were involved in data curation, methodology, project administration, supervision,
71 investigation and writing and reviewing the manuscript. NGM, YM, EP, MR, SR, HR,
72 MV, AJP were involved in data curation, formal analysis, investigation, methodology
73 and writing and reviewing the manuscript. All authors critically reviewed and approved
74 the final version.

75

76 **Abstract**

77 Duration of protection from SARS-CoV-2 infection in people with HIV (PWH) following
78 vaccination is unclear. In a sub-study of the phase 2/3 the COV002 trial
79 (NCT04400838), 54 HIV positive male participants on antiretroviral therapy
80 (undetectable viral loads, CD4+ T cells >350 cells/ul) received two doses of ChAdOx1
81 nCoV-19 (AZD1222) 4-6 weeks apart and were followed for 6 months. Responses to
82 vaccination were determined by serology (IgG ELISA and MesoScale Discovery
83 (MSD)), neutralisation, ACE-2 inhibition, gamma interferon ELISpot, activation-
84 induced marker (AIM) assay and T cell proliferation. We show that 6 months after
85 vaccination the majority of measurable immune responses were greater than pre-
86 vaccination baseline, but with evidence of a decline in both humoral and cell mediated
87 immunity. There was, however, no significant difference compared to a cohort of HIV-
88 uninfected individuals vaccinated with the same regimen. Responses to the variants
89 of concern were detectable, although were lower than wild type. Pre-existing cross-
90 reactive T cell responses to SARS-CoV-2 spike were associated with greater post-
91 vaccine immunity and correlated with prior exposure to beta coronaviruses. These
92 data support the on-going policy to vaccinate PWH against SARS-CoV-2, and
93 underpin the need for long-term monitoring of responses after vaccination.

94

95 **Introduction**

96 The global COVID-19 pandemic has led to over 200 million cases and 4.2 million
97 deaths (1). Vaccines which have been licensed against SARS-CoV-2 include the
98 AstraZeneca ChAdOx1 nCov-19 (AZD1222) adenoviral vectored vaccine, of which
99 over 1 billion doses have been made available worldwide. People living with HIV
100 (PWH) represent a high-risk group for adverse clinical outcomes from viral infections
101 such as influenza and COVID-19, with some evidence for higher hospitalisation and
102 mortality rates (2-6). This can in part be attributed to a state of immune cell depletion
103 and chronic immunopathology including immune activation and exhaustion which is
104 only partially restored by antiretroviral therapy (ART)(7, 8). Studies on influenza and
105 tetanus toxin vaccination in PWH have shown that antibody levels post-vaccination
106 were dependent on CD4 T cell count and activated T follicular helper (Tfh) cell
107 frequencies, which can vary widely in PWH (9, 10), resulting in broader concerns over
108 reduced responses to vaccines (11) and specific vaccination guidelines for PWH (12).
109 Some studies also report that vaccination of PWH may induce immune activation and
110 reactivate the HIV reservoir (13, 14).

111

112 ChAdOx1 nCov-19 containing SARS-CoV-2 full length spike has been shown to
113 induce potent humoral and cellular immune response in vaccine recipients (15-18).
114 We recently reported the safety and immunogenicity of the ChAdOx1 nCoV-19
115 vaccine in PWH up to 2 months post initial vaccination (16) and the durability of T and
116 B cell responses following natural infection with SARS-CoV-2 (19). There are,
117 however, few studies evaluating the durability of immunity following vaccination
118 against COVID-19 (20, 21). A recent open label phase I trial showed durable SARS-
119 CoV-2 T and B cell immune response up to 6 months following vaccination in adults

120 without HIV using a low dose of mRNA vaccine mRNA-1273 (21), with similar results
121 in another study using standard mRNA-1273 dosing (22). There have been no studies
122 to date reporting the durability of immune responses in PWH.

123

124 Since the rollout of COVID-19 vaccines, divergent mutations in the viral sequence in
125 the original SARS-CoV-2 strain have given rise to the alpha (B.1.1.7), beta (B.1.351),
126 gamma (P.1), and more recently delta (B.1.617.2) variants of concern (VOCs).
127 Infections with VOCs have become dominant in several countries (23). Studies of
128 symptomatic disease in fully vaccinated individuals report variable effectiveness
129 (ChAdOx1 nCoV-19 – alpha (74%), delta (67%) and BNT162b2 – alpha (93.7%), delta
130 (88%)), but with evidence for sustained protection from severe disease (24-26).
131 Nonetheless, breakthrough infections have been recorded and a significant proportion
132 of the world's population remains unvaccinated (27). Understanding the ability of
133 immune responses generated in PWH to recognise VOCs is key to informing
134 vaccination strategies, especially in vulnerable populations.

135

136 Pre-existing cross-reactive T and B cell responses in individuals naïve to SARS-CoV-
137 2 infection and vaccination to the circulating common cold coronaviruses (CCC)
138 HKU1, OC43, 299E and NL63 have been identified (28-34), however the impact of
139 this cross-reactivity is unclear. While some reports point to a beneficial role in
140 mitigating disease severity and the induction of neutralising antibodies in both
141 vaccination and natural infection (33, 35, 36), others report no biological function (37,
142 38) or a potential pathological role (39).

143

144 In this open-label, non-randomised sub-study of male participants with HIV on ART
145 (CD4+ T cell count >350 cells/ul) receiving ChAdOx1 nCoV-19, we investigate the
146 immunological landscape six months after vaccination. We evaluate the durability of
147 the cellular and humoral immune response to SARS-CoV-2 and VOCs and assess the
148 potential role of cross-reactive CCC immune responses in the modulation of post-
149 vaccine responses, presenting evidence for an interaction with the beta coronaviruses,
150 HKU1 and OC43.

151

152 **Results**

153 **Participants**

154 PWH (N=54; all male) were recruited as part of the ChAdOx1 nCoV-19 COV002
155 clinical trial (NCT04400838) in November 2020. Participants had undetectable VL
156 (<50 HIV RNA copies/ml) and a median CD4 count of 694 cells/ μ l (IQR 573.5 – 859.5)
157 at the time of recruitment. Most participants were of white ethnicity (81.5%). Other
158 reported ethnicities were Asian (3.7%), mixed (7.4%) and other (7.4%).
159 Demographically-matched HIV seronegative controls were provided from the
160 ChAdOx1 nCoV-19 COV002 clinical trial. All participants received ChAdOx1 nCoV-19
161 4-6 weeks apart and were followed for 6 months (**Figure 1a, Table 1**).

162

163 **Persistent immune activation in PWH before and after vaccination**

164 T cell immune activation and exhaustion were assayed at day 0 baseline, day 42 and
165 day 182 after first ChAdOx1 nCoV-19 vaccination (**Figure 1b-g**). There were
166 significantly higher frequencies of CD38+ HLA-DR+ expressing CD4+ and CD8+ cells
167 in PWH compared to HIV negative controls, consistent across all timepoints (**Figure**
168 **1b and e**, gating strategy in **supplementary figure 1a**). There was a transient

169 increase in the frequency of CD38+ HLA-DR+ CD4 and CD8+ T cells 14 days after
170 vaccination in PWH which returned to pre-vaccination levels by 6 months
171 **(Supplementary figure 1c, f)**. Expression of the immune checkpoint inhibitor PD-1
172 on CD4+ and CD8+ T cells was not significantly different between PWH and HIV
173 negative controls with no statistically significant changes after vaccination **(Figure 1c**
174 **and f)**. The frequency of CD4+ and CD8+ PD-1 expressing cells fluctuated early after
175 vaccination in PWH but was restored to pre-vaccination levels at 6 months
176 **(supplementary figure d, g, j and m)**. The frequency of functionally exhausted Tbet
177 (lo) Eomesodermin (Eomes) (hi) CD4+ and CD8+ T cells was higher in PWH
178 compared to HIV-negative individuals both before and after vaccination. **(Figure 1d**
179 **and g, supplementary figure 1e, h, k and n)**.

180

181 **Humoral immunity against ChAdOx1 nCoV-19 in PWH persists for 6 months.**

182 We previously reported detectable antibody levels up to 56 days following ChAdOx1
183 nCoV-19 vaccination in PWH (16). To determine the further persistence of antibody
184 responses, total IgG for spike (S), receptor binding domain (RBD) and nucleocapsid
185 (N), as well as neutralising antibody levels were measured at days 0 and day 182.
186 Two independent ELISA technologies were used for binding IgG assays: a
187 standardised in-house total IgG against spike and Meso Scale Discovery (MSD)
188 binding assays measuring S, RBD and N antibody levels. Levels of anti-spike IgG
189 measured using the two assays were positively correlated **(Supplementary figure 2a**
190 **and b**, $r=0.7$, $p<0.0001$ and $r = 0.9$, $p<0.0001$ at Days 0 and 182, respectively;
191 Spearman). At day 182 post-vaccination, antibodies to S and RBD but not N were
192 significantly higher than at baseline (S: day 0 = 3/43 [6.9%], day 182 = 35/42 [83.3%];

193 RBD: day 0 = 0/43 [0%] and day 182 = 27/42 [64.2%]) (**Figure 2a – c**), consistent with
194 observed responses being driven by vaccination rather than infection.

195

196 Importantly, there was no difference in anti-spike antibody titres in HIV+ and HIV-
197 matched participants measured at 182 days after first vaccination, although with some
198 waning of responses in both groups after Day 56 (**Figure 2d; Supplementary Figure**
199 **2d,e**). Pre-vaccine baseline antibody titres correlated positively with early post-
200 vaccination timepoints at day 14, and 28 but not 42, 56 and 182 (**Supplementary**
201 **figure 2f, Supplementary table 1**).

202

203 We next assessed the ability of antibodies from plasma collected 6 months after
204 vaccination to compete with SARS-CoV-2 for binding to ACE-2 using an ACE-2
205 inhibition assay and to neutralise SARS-CoV-2 using a live virus focus reduction
206 neutralisation assay (FRNT). FRNT was performed in a randomly selected subset of
207 the cohort for whom we have previously reported neutralisation antibody levels up to
208 day 56 (16). At day 182 post-ChAdOx1 nCoV-19 prime, antibodies capable of blocking
209 the SARS-CoV-2 ACE-2 interaction were present at significantly higher levels than at
210 pre-vaccination baseline (**Figure 2e**) and correlated strongly with anti-RBD antibodies
211 (**Supplementary figure 2c**). However, at the same time point antibody neutralisation
212 measured by FRNT live virus assay revealed titres below the assay detection limit in
213 nearly all participants (13/14; 92%) (**Figure 2f**).

214

215 **Durable SARS-CoV-2 specific T cell responses are induced following ChAdOx1** 216 **nCoV-19 vaccination**

217 Durability of vaccine-induced SARS-CoV-2-specific T cell immunity at 6 months was
218 assessed by IFN γ ELISpot and T cell proliferation assays. SARS-CoV-2 spike-specific

219 ELISpot responses were maintained for 6 months in PWH following vaccination and
220 were equivalent to the HIV negative control group (**Figure 3a and b; Supplementary**
221 **figure 4a**).

222

223 For further resolution of the durability of T cell immunity, we used a T cell proliferation
224 assay which also allows distinction of different CD4 and CD8 T cell lineage responses.
225 The spike peptide pool was separated into S1 and S2. Gating strategy is shown in
226 **Supplementary Figure 3a**. The frequency of SARS-CoV-2 spike-specific proliferative
227 CD4+ and CD8+ T cell responses in PWH following vaccination were maintained at
228 levels significantly higher than at baseline for 6 months (**Figure 3c - f**). Longitudinal
229 responses to FECT controls remained unchanged while PHA responses were back to
230 baseline by day 182 (**Supplementary figure 3b and c**). There was no difference in
231 the magnitude of the vaccine-specific T cell proliferative responses between the HIV+
232 and the HIV- cohorts (**Supplementary Figure 4f - I**). Although T cell responses in
233 PWH measured by IFN γ ELISpot peaked at day 14 and were then maintained to day
234 182, proliferative responses peaked later at day 42 and then contracted, such that day
235 182 responses were significantly lower than those measured at day 56 (**Figure 3c-f**).
236 These kinetics are similar to those observed with the anti-S antibody response
237 (**Supplementary figure 2d and e**).

238

239 **Vaccine-reactive T cells are not differentially biased to a specific CD4+ subset.**
240 Using CCR6 and CXCR3 expression to quantify Th1, Th2 and Th17 cells, we
241 interrogated the phenotype of circulating T cells following vaccination (gating strategy
242 in **Supplementary Figure 1a**). At 6 months post ChAdOx1 nCoV-19 vaccination, we
243 found redistributions in the phenotype of the CD4+ T cells in HIV+ volunteers with

244 increases in Th1 (CXCR3+ CCR6-) and Th2 (CXCR3- CCR6-) (**Figure 4a and b**) but
245 not Th17 (CXCR3- CCR6+) or Tfh (CXCR5+ CD4+) (**Figure 4c and d**). None of these
246 populations correlated with anti-spike antibody levels 6 months after infection.
247 Although the hierarchy in cellular composition of the CD4+ T cell subsets was similar
248 in the HIV+ and HIV- cohorts, we found circulating frequencies of Th2 subsets to be
249 reduced while Th1 and Tfh subsets were significantly increased 6 months after
250 vaccination in PWH (**Figure 4e, Supplementary Figure 5a** – for HIV- control data).

251
252 The activation induced marker (AIM) assay was used to determine the phenotype of
253 vaccine-specific CD4+ T cells 6 months after ChAdOx1 nCoV-19 vaccination (gating
254 strategy in **Supplementary figure 5b**). Vaccine responses were compared with
255 concurrent HIV Gag and CMV responses (**Figure 4f and g**). Although AIM+ cells for
256 all antigens tested showed a Th17 bias (**Supplementary Figure 5c**), similar to HIV-
257 Gag or CMVpp65-specific T cells there was no preferential skewing of the SARS-CoV-
258 2-specific T responses to any CD4 T helper subset 6 months after vaccination (**Figure**
259 **4h - k**).

260
261 **Responses to variants of concerns (VOCs) are preserved 6 months after**
262 **vaccination**

263 Humoral and cellular immune responses to the major VOCs were measured 6 months
264 after vaccination. Inhibition of ACE-2 binding for alpha, beta and gamma variants was
265 increased compared to pre-vaccination baseline (**Figure 5a**), however there was
266 statistically significant reduction in ACE-2 inhibition for all three VOCs compared to
267 the original SARS-CoV-2 strain, which was more apparent in the beta and gamma
268 variants (**Figure 5b**). T cell proliferative responses to VOCs were comparable to the

269 SARS-CoV-2 original strain, except for SARS-CoV-2 CD4 responses to S2 which were
270 moderately reduced across all VOCs tested (**Figure 5c – f**). HIV+ and HIV-
271 participants had similar magnitudes of T cell responses to S1 and S2 spike proteins of
272 all VOCs tested, with the exception of the CD8+ SARS-CoV-2 T cell proliferative
273 response targeting the S2 protein of the delta variant which showed a modest
274 reduction in HIV+ participants compared to HIV- controls (**Figure 5g – j**).

275

276 **Modulation of ChAdOx1 nCoV-19 post vaccination responses by pre-existing** 277 **cross-reactive immunity**

278 SARS-CoV-2 reactive T and B cells exist in unvaccinated COVID-19 naïve individuals
279 (**Figure 3a – e, Supplementary figure 2d and e**). To determine whether these pre-
280 vaccine responses might reflect cross-reactivity to endemic circulating coronaviruses
281 of the alpha (NL63 and 299E) or beta (HKU1, OC43) genera, we also measured
282 responses to these viruses at baseline.

283

284 Based on the T cell proliferation assay, participants were divided according to those
285 with pre-vaccine baseline SARS-CoV-2 immune responses ('baseline responders',
286 (BR)) and those without pre-existing immunity ('baseline non-responders', (B-NR)).
287 Regardless of any pre-existing immunity, all donors mounted an immune response
288 following vaccination, however BR consistently showed higher magnitude CD4+
289 (**Figure 6a and b**) and CD8+ T cell (**Supplementary Figure 6a and b**) responses to
290 SARS-CoV-2 S1 and S2 at most post-vaccination timepoints. Baseline SARS-CoV-2
291 CD4+ S2 (and to a lesser extent S1) T cell proliferation was positively correlated with
292 subsequent post-vaccine proliferative responses targeting the same regions

293 **(Supplementary Figure 7b and c, supplementary table 2a - d)**, which is of potential
294 interest as S2 is associated with regions of homology to other coronaviruses.

295 T cell and IgG responses to the endemic CCCs (HKU1 (clade 1 and 2), OC43, 299E
296 and NL63) in HIV-infected participants remained mostly unchanged by vaccination
297 with ChAdOx1 nCov-19 indicating that vaccination did not boost these responses
298 **(Figure 7c, Supplementary Figure 8 and 9)** however, IgG responses to SARS-CoV-
299 1 and MERS-CoV in PWH were higher at 6 months **(Figure 7a,b)**.

300

301 Focusing on baseline pre-existing responses – and dividing the cohort of PWH into
302 the SARS-CoV-2 BR and B-NR groups as before - participants with baseline
303 proliferative T cell responses to SARS-CoV-2 spike, also had T cell responses
304 targeting the S2 spike regions of CCCs, especially for the beta coronaviruses HKU1
305 and OC43 and alpha coronavirus 299E **(Figure 6c and d, Supplementary Figure 6c**
306 **and d, Supplementary table 3)**. This was supported by humoral responses taken at
307 the same pre-vaccination timepoint, which showed strong correlations between
308 SARS-Cov-2 spike IgG levels and those of SARS-CoV-1, MERS-CoV-1 and HKU1
309 **(Figure 7d-f; Supplementary Figure 9, supplementary table 4)**. Phylogenetic
310 analysis of spike sequences shows OC43 and HKU1 are the mostly closely related
311 CCCs to SARS-CoV-2 **(Figure 7g)**. These data suggest that prior exposure to beta
312 coronaviruses and responses to the S2 homologous region may potentially be
313 associated with larger and more persistent T cell responses following SARS-CoV-2
314 vaccination.

315 **Discussion**

316 Long-lasting immune responses against SARS-CoV-2 will be necessary to confer
317 protection from severe COVID-19. Although clinical management and effective
318 antiretroviral therapy (ART) have improved long-term outcomes for PWH – especially
319 in resource-rich countries – HIV-induced immunopathology evidenced by immune
320 activation and exhaustion does not recover to the levels found in HIV uninfected
321 subjects (40), raising concerns whether effective immune responses will persist after
322 vaccination. We show here for the first time in PWH that vaccine-induced immunity to
323 SARS-CoV-2 persists for at least 6 months by most assays, but with evidence that
324 responses are starting to wane. There were no significant differences in responses by
325 PWH and HIV- controls, extending the data from short-term responses reported
326 previously (16, 41).

327

328 We confirm the persistent immune activation - and, to a lesser degree, functional
329 exhaustion - in T cells in PWH on ART, but show that this does not impact the robust
330 humoral and cellular immune responses to ChAdOx nCoV-19 that persist for 6 months.
331 Reports on reactivation of the HIV reservoir and increased immune activation after
332 vaccination in PWH are conflicting (13, 14, 42), and although we found a transient
333 increase in the frequencies of T cells co-expressing CD38 and HLA-DR, this was
334 restored to baseline by six months. Further studies will be needed to determine any
335 impact on the HIV reservoir.

336

337 Vaccine design and regimen can skew the quality of the T cell response by the
338 preferential induction of one CD4+ T helper subset over another (43-48). ChAdOx-1
339 nCoV-19 responses show a qualitative skew towards the Th1 phenotype, with

340 increased IFN γ , IL-2 and TNF-producing T cells shortly after vaccination (18). Other
341 studies in convalescent cohorts have linked a CCR6⁺ Th-17 cTfh phenotype with
342 reduced disease severity (49). Similar to others (44, 50), we found antigen-specific
343 CD4⁺T cells following vaccination were mostly a CCR6⁺ CXCR3⁻ Th-17 phenotype.
344 We did not find SARS-CoV-2 spike-specific CD4⁺ T cells biased towards any
345 chemokine-expressing sub-population 6 months after vaccination, possibly reflecting
346 the longer duration between vaccination and analysis than in other studies.

347

348 Understanding durability of both humoral and cellular immunity to SARS-CoV-2 – both
349 likely key components of an effective response (49, 51, 52) - is key to understanding
350 long-term protection. When we assessed the longevity of the humoral and cellular
351 immunity in PWH 6 months after ChAdOx1 nCoV-19 vaccination, we found that
352 vaccine-mediated antibodies to spike or RBD remained elevated above baseline and
353 no different to HIV- controls. Similarly, T cell responses to spike were maintained at
354 magnitudes above baseline and demonstrated similar kinetics to HIV- participants.
355 Antibody function measured by ACE-2 binding inhibition was sustained at levels above
356 pre-vaccination, however live neutralisation assays did not detect antibodies in the
357 majority of the participants assayed at 6 months. Both assays identified the same
358 participants as low (n = 13) and high (n = 1) responders, and the ACE-2 binding
359 inhibition and SARS-CoV-2 RBD titres showed a strong positive correlation. We
360 speculate that although differences in positive responses between the two functional
361 assays could be as a result of function (neutralisation) versus antigenicity (ACE-2
362 binding inhibition), it could also in part, be due to assay sensitivity and differing
363 dynamic ranges between assays.

364

365 SARS-CoV-2 convalescent plasma has been shown to have effective FC-mediated
366 antibody functions such as antibody dependent cellular phagocytosis (ADCP),
367 antibody dependent cellular cytotoxicity (ADCC) and complement dependent
368 cytotoxicity (CDC) (53-55), which are more durable than neutralisation (54). Non-
369 neutralising functions were not evaluated in this study, and therefore we cannot
370 exclude that these are preserved in this cohort of PWH. Total spike IgG antibody and
371 T cell proliferative responses in PWH were significantly lower at 6 months after
372 vaccination compared to day 56. These results suggest detectable but waning T and
373 B cell responses at 6 months. Similar findings were reported for the mRNA-1273
374 COVID-19 vaccine, and found to be age-dependent, pointing to immune aging as a
375 contributing factor (20, 21). This comprehensive analysis of humoral and cellular
376 immunity is consistent with studies of COVID-19 in healthy adults and PWH showing
377 durable immune responses up to 7 months post infection (19, 52, 56, 57). Further
378 follow up at 12 months and beyond will be important to determine the longer-term
379 persistence of responses, especially when considering the value of booster doses.

380

381 The emergence of VOCs poses a potential roadblock to ending the pandemic. We
382 found humoral immunity to VOCs at 6 months to be at titres lower than those targeting
383 the original wild type (WT) SARS-CoV-2 strain, albeit still significantly higher than pre-
384 vaccination levels. The magnitude of the T cell responses to VOCs were similar to
385 those targeting the WT SARS-CoV-2 strain for most VOCs tested apart from the CD4+
386 S2 responses. For most of the VOCs, T cell responses in PWH did not differ from HIV-
387 controls. Similar observations regarding humoral immunity have been made with the
388 mRNA vaccine BNT162b2 although as most of these studies were done within 2
389 months of vaccination, information on durability of the response is lacking (58-60).

390 One study assessing T cell responses between 21 – 28 days after full BNT162b2
391 vaccination found no differences between WT and VOC CD4 responses (58). This
392 study utilised a pool of spike peptide pools not parsed into its S1 and S2 regions, and
393 only a limited panel of VOCs were analysed. Importantly, emerging data from real
394 world effectiveness studies suggest that vaccination protects against death and
395 severe disease, even following infection with VOCs (24, 26)

396

397 Cross-reactivity from previous CCC infection may impact the measured SARS-CoV-2
398 immune response after vaccination and natural infection (32, 33, 61). We identified
399 measurable pre-vaccine antibody titres for SARS-CoV-2 S, RBD and N proteins in
400 PWH. Pre-vaccination SARS-CoV-2 S antibody levels strongly correlated with those
401 of contemporaneous beta coronaviruses SARS-CoV-1, MERS-CoV and HKU1 (of
402 which only the latter is likely to have been experienced by these UK study participants),
403 supporting the hypothesis that these titres result from previous infection with a similar
404 coronavirus and some cross-reactivity across coronaviruses. Supporting the antibody
405 data, the presence of cross-reactive T cells pre-vaccination (based on proliferative
406 potential following antigen challenge) was associated with higher magnitude post-
407 vaccination T cell responses.

408

409 There is much debate over the significance of cross-reactive responses. Studies have
410 reported reduced disease severity in patients with CCC humoral responses and
411 regions of high homology to CCC capable of trans-priming SARS-CoV-2 T and B cell
412 responses (32, 33, 36). Pre-existing immunity was also shown to boost post vaccine
413 responses in low dose mRNA-1273 vaccine (21) although an explanatory mechanism
414 was not reported. Further investigations in large studies would be needed to fully

415 elucidate the impact of baseline pre-existing immunity in post-vaccination response,
416 but we find clear evidence of higher magnitude immune responses in those with cross-
417 reactivity. Although our data suggest that responses to CCC may help augment
418 subsequent vaccine responses against SARS-CoV-2, we have no evidence that on
419 their own they are potent enough to impact susceptibility to COVID-19.

420

421 In summary, we present a comprehensive immunological assessment of ChAdOx1
422 nCoV-19 in PWH 6 months after vaccination. We show that despite persistent immune
423 activation in PWH, PWH on ART and HIV-uninfected participants make equivalent T
424 and B cell responses following vaccination. However, both responses showed signs
425 of decline after 6 months. It is unknown what level of immunity is required to prevent
426 hospitalisation and mortality, but real-world data suggest vaccination is successful in
427 preventing severe disease and death even in the presence of transmissible and
428 virulent VOC (24, 26). A booster dose may become necessary in the future to maintain
429 long-term immunological memory to SARS-CoV-2 and the VOCs, especially for
430 susceptible cohorts and we must continue to carefully monitor this going forward.
431 Finally, we demonstrate that pre-existing SARS-CoV-2 cross-reactive immune
432 responses to the beta coronaviruses HKU1 and to a lesser extent OC43 are
433 associated with higher magnitude T cell responses following vaccination in PWH.
434 Together these data continue to reinforce the policy of ensuring all PWH are offered
435 vaccination against SARS-CoV-2.

436 **Methods**

437 ***Study design and cohort***

438 The cohort studied in this analysis has been described previously (16). Briefly, the
439 study comprised people living with HIV in an open-label non-randomised group within
440 the larger multicentre phase 2/3 COV002 trial. The participants in this single-arm group
441 comprised individuals with HIV who were stable on ART under routine follow-up at two
442 London UK National Health Service (NHS) clinics and received ChAdOx1 nCoV-19
443 vaccination according to the schedule of attendance. Recruitment was done in HIV
444 clinics at two centres in the UK (Imperial College NHS Trust and Guy's and St Thomas'
445 NHS Foundation Trust). Inclusion criteria were age 18–55 years, a diagnosis of HIV
446 infection, virological suppression on ART at enrolment (plasma HIV viral load <50
447 copies per mL), and a CD4 count of more than 350 cells/ μ L. The inclusion criteria for
448 the COV002 trial have been published in full elsewhere (15). Written informed consent
449 was obtained from all participants, and the trial was done in accordance with the
450 principles of the Declaration of Helsinki and Good Clinical Practice. Study approval in
451 the UK was done by the Medicines and Healthcare products Regulatory Agency
452 (reference 21584/0424/001-0001) and the South Central Berkshire Research Ethics
453 Committee (reference 20/SC/0145). Vaccine use was authorised by Genetically
454 Modified Organisms Safety Committees at each participating site.

455 The ChAdOx1 nCoV-19 vaccine was produced as previously described (17).
456 Participants received two standard intramuscular doses 4–6 weeks apart. For some
457 assays and where sample availability allowed, comparison was made with age- and
458 sex-matched participants who were HIV negative, aged 18–55 years, enrolled into the
459 main COV002 phase 2/3 randomised clinical trial, and randomly assigned (5:1) to
460 receive either ChAdOx1 nCoV-19 or MenACWY by intramuscular vaccination. The

461 dose of vaccine administered was the same across both groups. Only participants
462 receiving the ChAdOx1 nCoV-19 vaccine were used for comparison. Full details of the
463 COV002 HIV-negative cohort have been published previously (15).

464 A screening visit where a full medical history, examination of all participants and blood
465 tests to exclude biochemical or haematological abnormalities (full blood count; kidney
466 and liver function tests) was done prior to enrolment. Participants with a history of
467 laboratory-confirmed SARS-CoV-2 infection by anti-N protein IgG immunoassay
468 (Abbott Architect, Abbott Park, IL, USA) at screening were excluded. For this study,
469 visits on day 0 (vaccine prime) and 182 were the main study timepoints used for
470 immunological analysis however for some assays other study visits - 14, 28 (vaccine
471 boost), 42, and 56 - are presented where available. As some participants did not attend
472 for their day 182 visit (n=6), there is a maximum of n=48 at this timepoint.

473

474 ***Mesoscale Discovery (MSD) binding assays***

475 IgG responses to SARS-CoV-2, SARS-CoV-1, MERS-CoV and
476 seasonal coronaviruses were measured using a multiplexed MSD immunoassay. The
477 V-PLEX COVID-19 Coronavirus Panel 3 (IgG) Kit (cat. no. K15399U) from Meso Scale
478 Diagnostics, Rockville, MD USA. A MULTI-SPOT® 96-well, 10 spot plate was coated
479 with three SARS CoV-2 antigens (S, RBD, N), SARS-CoV-1 and MERS-CoV spike
480 trimers, as well as spike proteins from seasonal human coronaviruses, HCoV-OC43,
481 HCoV-HKU1, HCoV-229E and HCoV-NL63, and bovine serum albumin. Antigens
482 were spotted at 200–400 µg/mL (MSD® Coronavirus Plate 3). Multiplex MSD assays
483 were performed as per the instructions of the manufacturer. To measure IgG
484 antibodies, 96-well plates were blocked with MSD Blocker A for 30 minutes. Following
485 washing with washing buffer, samples diluted 1:1,000-10,000 in diluent buffer, or MSD

486 standard or undiluted internal MSD controls, were added to the wells. After 2-hour
487 incubation and a washing step, detection antibody (MSD SULFO-TAG™ Anti-Human
488 IgG Antibody, 1/200) was added. Following washing, MSD GOLD™ Read Buffer B
489 was added and plates were read using a MESO® SECTOR S 600 Reader. The
490 standard curve was established by fitting the signals from the standard using a 4-
491 parameter logistic model. Concentrations of samples were determined from the
492 electrochemiluminescence signals by back-fitting to the standard curve and multiplied
493 by the dilution factor. Concentrations are expressed in Arbitrary Units/ml (AU/ml). Cut-
494 offs were determined for each SARS-CoV-2 antigen (S, RBD and N) based on the
495 concentrations measured in 103 pre-pandemic sera + 3 Standard Deviations. Cut-off
496 for S: 1160 AU/ml; cut-off for RBD: 1169 AU/ml; cut-off for N: 3874 AU/ml.

497

498 ***SARS CoV-2 spike IgG ELISA***

499 Humoral responses at baseline and following vaccination were assessed using a
500 standardised total IgG ELISA against trimeric SARS CoV-2 spike protein as described
501 previously²¹. In brief, ELISA plates were coated with 2 µg/mL of full-length trimerised
502 SARS-CoV-2 spike glycoprotein and stored at 4°C overnight for at least 16 hours. After
503 coating, plates were washed 6 times with PBS/0.05% Tween and blocked with casein
504 for 1h at room temperature (RT). Thawed samples were treated with 10% Triton X-
505 100 for 1h at RT and subsequently diluted in casein and plated in triplicate for
506 incubation for 2h at RT alongside two internal positive controls (controls 1 and 2) to
507 measure plate to plate variation. Control 1 was a dilution of convalescent plasma
508 sample and control 2 was a research reagent for anti-SARS-CoV-2 Ab (code 20/130
509 supplied by National Institute for Biological Standards and Control (NIBSC)). The
510 standard pool was used in a two-fold serial dilution to produce ten standard points that

511 were assigned arbitrary ELISA units (EUs). Goat anti-human IgG (γ -chain specific)
512 conjugated to alkaline phosphatase was used as secondary antibody and plates were
513 developed by adding 4-nitrophenyl phosphate in diethanolamine substrate buffer. An
514 ELx808 microplate reader (BioTek Instruments) was used to provide optical density
515 measurement of the plates at 405nm. Standardised EUs were determined from a
516 single dilution of each sample against the standard curve which was plotted using the
517 4-Parameter logistic model (Gen5 v3.09, BioTek). Each assay plate consisted of
518 samples and controls plated in triplicate, with ten standard points in duplicate and four
519 blank wells. The assay LLOQ (representing the lowest IgG titres that can be reliably
520 and precisely quantified within a coefficient of variation of 25%) was determined
521 mathematically. This was based on the 4-PL function of the standard curve data from
522 250 independent experiments and represents the EU value corresponding to the
523 upper 95% confidence interval of the minimum asymptote of the 4-PL curve fit used
524 for modelling the assay standard curves. The value of 13 EU was calculated as the
525 assay LLOQ and this corresponds to an OD value of 0.2 for which the assay was
526 demonstrated to show linearity.

527

528 ***Focus reduction neutralization assay (FRNT)***

529 Antibody neutralization was measured in a randomly selected subset of participants
530 using a Focus Reduction Neutralization Test (FRNT), as described previously (62)
531 where the reduction in the number of the infected foci is compared to a 'no antibody'
532 negative control well. Briefly, serially diluted Ab or plasma was mixed with SARS-CoV-
533 2 strain Victoria and incubated for 1 hour at 37°C. The mixtures were then transferred
534 to 96-well, cell culture-treated, flat-bottom microplate containing confluent Vero cell
535 monolayers in duplicate and incubated for further 2 hours, followed by the addition of

536 1.5% semi-solid carboxymethyl cellulose (CMC) overlay medium to each well to limit
537 virus diffusion. A focus forming assay was then performed by staining Vero cells with
538 human anti-NP mAb (mAb206) followed by peroxidase-conjugated goat anti-human
539 IgG (A0170; Sigma). Finally, the foci (infected cells) approximately 100 per well in the
540 absence of antibodies, were visualized by adding TrueBlue Peroxidase Substrate.
541 Virus-infected cell foci were counted on the classic AID ELISpot reader using AID
542 ELISpot software. The percentage of focus reduction was calculated and IC50
543 (reported as FRNT50) was determined using the probit program from the SPSS
544 package.

545

546 ***MSD ACE-2 inhibition assay***

547 A multiplexed MSD immunoassay (MSD, Rockville, MD) was used to measure the
548 ability of human sera to inhibit ACE2 binding to SRAS-CoV-2 spike (B, B.1,
549 B.1.1.7, B.1.351 or P.1). A MULTI-SPOT® 96-well, 10 Spot Plate (Plate 7) was
550 coated with eight SARS-CoV-2 spike and RBD antigens (B, B.1, B.1.1.7, B.1.351
551 or P.1). Multiplex MSD Assays were performed as per manufacturer's instructions.
552 To measure ACE2 inhibition, 96-well plates were blocked with MSD blocker for 30
553 minutes. Plates were then washed in MSD washing buffer, and samples were
554 diluted 1:10 and 1:100 in diluent buffer. Importantly, an ACE2 calibration curve
555 which consists of a monoclonal antibody with equivalent activity against spike
556 variants was used to interpolate results as arbitrary units. Furthermore, internal
557 controls and the WHO international standard were added to each plate. After 1-
558 hour incubation recombinant human ACE2-SULFO-TAG™ was added to all wells.
559 After a further 1-hour plates were washed and MSD GOLD™ Read Buffer B was

560 added, plates were then immediately read using a MESO® SECTOR S 600
561 Reader.

562

563 ***Isolation of peripheral blood mononuclear cells (PBMC) from whole blood***

564 PBMCs were isolated by density gradient centrifugation using Lymphoprep (Stem Cell
565 Technologies, Cambridge, UK). Buffy coats containing PBMCs were collected and
566 washed twice with pre-warmed R10 medium: Roswell Park Memorial Institute (also
567 known as RPMI) 1640 medium (Sigma Aldrich, St Louis, MO, USA) supplemented
568 with 10% heat-inactivated fetal calf serum (FCS; Sigma), 1 mM penicillin-streptomycin
569 solution (Sigma), and 2 mM L-glutamine solution (Sigma). After the second
570 centrifugation, cells were resuspended in R10 and counted using the Guava ViaCount
571 assay (Guava Technologies Hayward, CA, USA) on the Muse Cell Analyzer (Luminex
572 Cooperation). T-cell enzyme-linked immunospot assay (ELISpot) assays were done
573 on freshly isolated PBMCs, and CellTrace Violet (CTV; ThermoFisher Scientific, CA,
574 USA) T cell proliferation assay was done on cryopreserved samples.

575

576 ***Ex vivo IFN γ ELISpot to enumerate antigen-specific T cells.***

577 ELISpot assays were performed as described previously (17) using a validated
578 protocol with freshly isolated peripheral blood mononuclear cells (PBMCs) to
579 determine responses to the SARS-CoV-2 spike vaccine antigen at days 0 (before
580 vaccination), 14, 28 (boost), 42 and 56. Assays were performed using Multiscreen IP
581 ELISpot plates (Merck Millipore, Watford, UK) coated with 10 μ g/mL human anti-IFN γ
582 antibody and developed using SA-ALP antibody conjugate kits (Mabtech, Stockholm,
583 Sweden) and BCIP NBT-plus chromogenic substrate (Moss Inc., Pasadena, MA,
584 USA). PBMC were separated from whole blood with lithium heparin by density

585 centrifugation within four hours of venepuncture. Cells were incubated for 18–20 hours
586 in RPMI (Sigma) containing 1000 units/mL penicillin, 1 mg/mL streptomycin and 10%
587 heat-inactivated, sterile-filtered foetal calf serum, previously screened for low reactivity
588 (Labtech International, East Sussex, UK) with a final concentration of 10µg/ml of each
589 peptide. A total of 253 synthetic peptides (15mers overlapping by 10 amino acids)
590 spanning the entire vaccine insert, including the tPA leader sequence were used to
591 stimulate PBMC (ProImmune, Oxford UK). Peptides were pooled into 12 pools for the
592 SARS-CoV-2 spike protein containing 18 to 24 peptides, plus a single pool of 5
593 peptides for the tPA leader. Peptides were tested in triplicate, with 2.5×10^5 PBMC
594 added to each well of the ELISpot plate in a final volume of 100µL. Results are
595 expressed as spot forming cells (SFC) per million PBMCs, calculated by subtracting
596 the mean negative control response from the mean of each peptide pool response and
597 then summing the response for the 12 peptide pools spanning S1 and S2.
598 Staphylococcal enterotoxin B (0.02 µg/mL) and phytohaemagglutinin-L (10 µg/ mL)
599 were pooled and used as a positive control. Plates were counted using an AID
600 automated ELISpot counter (AID Diagnostika GmbH, algorithm C, Strassberg,
601 Germany) using identical settings for all plates, and counts were adjusted only to
602 remove artefacts. A lower limit of detection of 48 SFC/million PBMCs was determined
603 based on the minimum number of spots that could be detected.

604

605 ***T cell proliferation assay***

606 T cell proliferation assay was done using cryopreserved PBMCs. Briefly, PBMCs were
607 thawed and washed twice with 1mL of PBS followed by labelling with CTV at a final
608 concentration of 2.5 µM for 10 min at room temperature. CTV, a DNA intercalating
609 dye, enables the measurement of the decrease in dye concentration following each

610 cell division in proliferating cells in response to antigenic stimulation as described
611 previously (34). The labelling reaction was quenched with 4mL of fetal bovine serum
612 (FBS) at 4°C and cells were resuspended in RPMI medium supplemented with 10%
613 human blood group type AB serum (Sigma), 1 mM penicillin-streptomycin solution,
614 and 2 mM L-glutamine solution, and subsequently plated in a 96-well round bottom
615 plate at a plating density of 0.25×10^6 cells per well in duplicate wells (total of
616 0.5×10^6 cells per condition). Cells were stimulated with peptide pools (15nmers
617 overlapping by 11) spanning SARS-CoV-2 spike (S1 and S2), SARS-CoV-2 variants
618 of concern (beta, gamma and delta) and HCoV-229E (HKU-1 – 2 consensus clades, OC43,
619 NL63 and 229E) at a final concentration of 1 µg/mL per peptide. For antigenic control,
620 class 1 and 2 optimal peptides for FEC-T (flu, EBV, CMV, and tetanus) were pooled
621 at a final concentration of 1 µg/mL per peptide. Media, containing 0.1% dimethyl
622 sulfoxide (DMSO; Sigma) representing DMSO content in peptide pools, was used as
623 a negative control and 2 µg/mL phytohaemagglutinin L (Sigma) was used as positive
624 control. Cells were then incubated at 37°C, with 5% carbon dioxide and 95% humidity
625 for 7 days, with a change of media on day 4. At the end of the incubation period, cells
626 were stained using anti-human CD3, CD4, CD8, and a live cell discriminator
627 (Live/Dead near Infra-red, Life Technologies; ThermoFisher Scientific, CA, USA) as in
628 supplementary table 5. All samples were acquired using a BD Fortessa X20 (BD
629 Bioscience, San Jose, CA, USA) or MACSQuant x10 (Miltenyi Biotec, Bergisch
630 Gladbach, Germany). Responses above 1% were considered true positive based
631 mean of DMSO controls + 3x SD. Specificity of the assay has been previous reported
632 in (34). All datapoints presented represent a single participant and are presented as
633 background subtracted data.

634

635 **AIM Assay**

636 Cryopreserved PBMCs from 25 HIV infected subjects were used for activation induced
637 marker (AIM) assay. Briefly, PBMCs were thawed in R10 (RPMI + 10% FCS, 1%
638 Pen/strep and 1% L-glutamine. Cells were washed, counted, and rested for 6 hours in
639 IMDM-10 (Iscove's Modified Dulbecco's Medium - Sigma, I3390 + 10% Human AB
640 serum, 1% Pen/strep and 1% L-glutamine) and 1ul/ml of benzonase nucleases
641 (70746-3, Merck). Following rest, cells were plated at 1-2 x10⁶ cells/well in a 96 well
642 round bottom plate. Cells were then incubated for 24 hours at 37°C and 5% CO₂. After
643 stimulation cells were stained with the anti-human antibodies contained in
644 **supplementary table 6**. Stained cells were fixed in 4% PFA and acquired on a BD
645 LSR II flow cytometer. The data was analysed using FlowJo version 10 and Prism
646 version 9. Antigen-specific CD4⁺ and CD8⁺ T cells were gated using the gating
647 strategy described by Nielsen et al (44) and shown in **supplementary figure 5** (for
648 CD4 T cells: CD25⁺ CD134(OX40)⁺ and CD25⁺ CD137⁺ and CD25⁺ CD69⁺; for
649 CD8⁺ T cells: CD25⁺ CD137⁺ and CD25⁺ CD69⁺). Chemokine receptors CCR6 and
650 CXCR3 were used as an unbiased way of analysing T cell skewness independent of
651 cytokine kinetics.

652

653 **Ex vivo activation and exhaustion assays**

654 Cryopreserved PBMCs were thawed in 30mls of RPMI media supplemented with 10%
655 FBS, 1% Pen-strep and 1% L-glutamine (R10). Cells were counted and rested for an
656 hour at a cell density of 2 x 10⁶ per ml of R10 in the presence of benzonase
657 endonucleases (70746-3, Merck). Following rest, 2-3 million cells were used for each
658 of the panels. Cells were washed in staining buffer (420201, Biolegend). This was
659 followed by blocking FC receptors (422302, Biolegend) for 10 minutes at room

660 temperature (RT) and live cell staining using L/D aqua (L34966, Life Technologies). All
661 cells were then washed in preparation for antibody staining. For ex vivo
662 immune activation panel, antibodies for assessing immune activation (as listed
663 in supplementary table 7) was used as a cocktail and added to the cell pellet. Cells
664 were subsequently incubated at 37°C for 15 minutes which was followed by
665 a wash and fixation in 4% paraformaldehyde (PFA) for 10 minutes at RT. PFA was
666 washed off and cells resuspended in PBS for acquisition on flow cytometer. For
667 immune exhaustion panel, antibodies for surface markers were prepared in a cocktail
668 which was added to cells and incubated for 15 minutes at 37°C (supplementary table
669 8). Cells were then prepared for intranuclear stain using FOXP3
670 fixation/permeabilisation kit (Life technologies). Briefly, 100ul of fixation buffer was
671 added to cells and incubated at RT for 30 minutes. This was followed by cellular
672 permeabilisation using the permeabilisation buffer contained in the aforementioned kit.
673 Antibody cocktails were prepared in permeabilisation buffer, added to cells and
674 allowed to incubate for 30 minutes at RT. Following staining, cells were washed and
675 resuspended in PBS for acquisition. All data was acquired on a BD LSR II flow
676 cytometer and fluorescent minus one (FMO) gates were used to set gates for markers
677 of interest. Gating strategies are as shown in **supplementary figure 1a and b**

678

679 ***Phylogenetic analysis***

680 We used protein BLAST to download all human coronavirus S protein sequences from
681 NCBI database. We then randomly chose 3 sequences for each of the human
682 coronavirus species. HKU1 was consisted of two clades and we chose three isolates
683 for each clade (c1 and c2). We used MAFFT to align all chosen human corona viruses,
684 SARS-CoV, MERS-CoV and SARS-CoV-2 S protein sequences. We then calculated

685 the pairwise distances between the sequences and built a neighbour joining tree using
686 MATLAB.

687

688 ***Statistical analysis***

689 This study was not powered to a specific endpoint and the sample size was based on
690 practical recruitment considerations in line with other subgroups of the COV002 study.

691 We analysed all outcomes in all participants who received both doses of the
692 vaccination schedule and with available samples, unless otherwise specified. We log-

693 transformed serological, FRNT50, and ELISpot data for analysis. FRNT50 titres less

694 than 20 were given the value 10 for statistical analysis. We present medians and IQRs

695 for immunological endpoints. We used non-parametric analysis (Spearman's rho) for

696 correlations between two immunological endpoints. For comparison of two non-

697 parametrically distributed unpaired variables, we used the Wilcoxon rank sum (Mann

698 Whitney *U*) test. For comparison of two non-parametrically distributed paired datasets,

699 we used the Wilcoxon matched pairs signed rank test. We used the χ^2 test for

700 comparison of ELISpot responses. Missing data were not imputed. We did all analyses

701 using R (version 3.6.1 or later), and Prism 9 (GraphPad Software). The COV002 study

702 is registered with [ClinicalTrials.gov](#), [NCT04400838](#), and is ongoing.

703

704 ***Role of the funding source***

705 The funders of the study had no role in the study design, data collection, data analysis,

706 data interpretation, or writing of the report. All authors had full access to all the data in

707 the study and had final responsibility for the decision to submit for publication.

708

709 **Acknowledgements**

710 This Article reports independent research funded by UK Research and Innovation
711 (MC_PC_19055), Engineering and Physical Sciences Research Council
712 (EP/R013756/1), Coalition for Epidemic Preparedness Innovations, and NIHR. We
713 acknowledge support from Thames Valley and South Midland's NIHR Clinical
714 Research Network and the staff and resources of NIHR Southampton Clinical
715 Research Facility and the NIHR Oxford Health Biomedical Research Centre. PMF
716 received funding from the Coordenacao de Aperfeicoamento de Pessoal de Nivel
717 Superior, Brazil (finance code 001). ALF was supported by the Chinese Academy of
718 Medical Sciences Innovation Fund for Medical Science, China (grant number 2018-
719 I2M-2-002). MAA is supported by the Wellcome Trust and Royal Society
720 (220171/Z/20/Z). KJE is an NIHR Biomedical Research Centre senior research fellow.
721 AJP and EB are NIHR senior investigators. M.C., S.L. and ToT. are funded by a U.S.
722 Food and Drug Administration Medical Countermeasures Initiative grant
723 75F40120C00085. The views expressed in this publication are those of the authors
724 and not necessarily those of the NIHR, FDA or the UK Department of Health and
725 Social Care. We thank the volunteers who participated in this study.

726

727 **Declaration of interests**

728 Oxford University has entered into a partnership with AstraZeneca for further
729 development of ChAdOx1 nCoV-19 (AZD1222). AstraZeneca reviewed the data from
730 the study and the final manuscript before submission, but the authors retained editorial
731 control. SCG is cofounder of Vaccitech (a collaborator in the early development of this
732 vaccine candidate) and named as an inventor on a patent covering use of ChAdOx1-
733 vectored vaccines (PCT/GB2012/000467) and a patent application covering this

734 SARS-CoV-2 vaccine. TL is named as an inventor on a patent application covering
735 this SARS-CoV-2 vaccine and was consultant to Vaccitech. PMF is a consultant to
736 Vaccitech. AJP is Chair of the UK Department of Health and Social Care's JCVI, but
737 does not participate in policy advice on coronavirus vaccines, and is a member of the
738 WHO Strategic Advisory Group of Experts (SAGE). AVSH is a cofounder of and
739 consultant to Vaccitech and is named as an inventor on a patent covering design and
740 use of ChAdOx1-vectored vaccines (PCT/GB2012/000467).

741 **Tables and table legend**

742

743 **Table 1: Demographic information for HIV infected and HIV uninfected receiving**
744 **ChAdOx1 nCoV-19**

745

746


		HIV infected	HIV uninfected	
Assay		All reported assays	ELISpot and ELISA	Activation/Exhaustion Panel, proliferation assay, and AIM assay
n		54	50	10
Sex	Male	54 (100%)	26 (52%)	10 (100%)
	Female	0 (0%)	24 (48%)	0 (0%)
Age in years		42.5 (37.2 - 49.8)	38.5 (29.2 - 45.0)	
Ethnicity	White	44 (81%)	40 (80%)	6 (60%)
	Black	0 (0%)	1 (2%)	1 (10%)
	Asian	2 (4%)	8 (16%)	2 (20%)
	Mixed	4 (7%)	0 (0%)	0 (0%)
	Other	4 (7%)	1 (2%)	1 (10%)
Antiretroviral therapy	Y	54 (100%)	NA	NA
	N		NA	NA
Plasma HIV VL		<50	NA	NA
CD4 count > 350 cells/ul		694.0 (573.5 - 859.5)	NA	NA

747

748 **Figures and Figure Legends**

749

Figure 1: PLWH show higher baseline immune activation and exhaustion




750

751

752 **Figure 1: PWH show higher baseline immune activation and exhaustion.**

753 **A)** Schematic showing vaccination schedule for ChAdOx1 nCoV-19 in PWH. Frequency of **(B)** CD38+ HLA-DR+, **(C)** PD1+ **(D)**
 754 Tbet(lo) Eomes(hi) cells within CD4+ and **(E)** CD38+ HLA-DR+, **(F)** PD1+ **(G)** Tbet(lo) Eomes(hi) cells within CD8+ T cells.
 755 Comparison of two groups by two-tailed Mann-Whitney U test. Where indicated * = <0.05, ** = <0.01, *** = < 0.001 and **** = <0.0001.

Figure 2: Antibody levels against SARS-CoV-2 6 months after ChAdOx1 nCoV-19 vaccination




756
757

Figure 2: Antibody levels against SARS-CoV-2 6 months after ChAdOx1 nCoV-19 vaccination.

758 IgG levels for SARS-CoV-2 (A) Spike (B) RBD and (C) N protein measured at day 0 (baseline) and day 182 (6 months post-
759 vaccination) using the MSD ELISA assays. (D) Comparison between antibody kinetics in HIV+ and HIV- across all available
760 timepoints. (E) ACE-2 inhibition assay at baseline and 6 months post-vaccination and (F) Live-virus focus reduction neutralisation
761 assay (FRNT) on n =15 HIV+ donors on day 0, 28, 56 and 182. Comparison of two timepoints within the same group was done by
762 Wilcoxon matched pair sign ranked test. Comparison of two groups was done by two-tailed Mann-Whitney U test. Where indicated *
763 = <0.05, ** = <0.01, *** = < 0.001 and **** = <0.000. Dotted lines in A – C indicate cut off points determined for each SARS-CoV-2
764 antigen (S, RBD and N) based on pre-pandemic sera + 3X SD.
765


Figure 3: T cell responses following ChAdOx1 nCoV-19 vaccination are durable in PWH.



767
768

769 **Figure 3: T cell responses following ChAdOx1 nCoV-19 vaccination are durable in PWH.**
 770 (A) T cell response measured using peptides pools against SARS-CoV-2 S1 and S2 antigens by IFN γ ELISpot across all timepoints.
 771 (B) comparative analysis of IFN γ T cell responses in HIV+ and HIV- volunteers. Proliferative T cell responses to (C) SARS-CoV-2 S1
 772 and (D) SARS-CoV-2 S2 in CD4+ T cells across all available timepoints. Proliferative T cell responses to (E) SARS-CoV-2 S1 and
 773 (F) SARS-CoV-2 S2 in CD8+ T cells across all available timepoints. Comparison of two timepoints within the same group was done
 774 by Wilcoxon matched pair sign ranked test. Comparison of two groups was done by two-tailed Mann-Whitney U test. Where indicated
 775 * = <0.05, ** = <0.01, *** = < 0.001 and **** = <0.000. Dotted lines in C - F indicate threshold for true positive based mean of DMSO
 776 controls + 3x SD.

Figure 4: SARS-CoV-2 specific T cells are not preferentially biased for any CD4+ T cell subsets




777
778

779 **Figure 4: SARS-CoV-2 specific T cells are not preferentially biased for any CD4+ T cell subsets.**

780 *Ex vivo* frequencies of **(A)** CXCR3+ CCR6- (Th1), **(B)** CXCR3- CCR6- (Th2), **(C)** CXCR3- CCR6+ (Th17), and **(D)** CXCR5+ within
781 CD4+ T cells in HIV+ volunteers measured at day 0, 42 and 182 using *ex vivo* T cell phenotyping. **(E)** comparative analysis of
782 frequencies of *ex vivo* CD4+ T cell frequencies in HIV+ and HIV- volunteers at day 182 (6 months post vaccination). Measurement
783 of frequencies of antigen specific T cells including SARS-CoV-2 S1 and S2, HIV gag and CMVpp65 using activation induced marker
784 (AIM) assay in **(F)** CD4+ and **(G)** CD8+ T cells. For CD4 T cells, antigen specific cells were: CD25+ CD134(OX40)+ and CD25+
785 CD137+ and CD25+ CD69+; for CD8+ T cells, antigen specific cells were: CD25+ CD137+ and CD25+ CD69+ Frequencies of **(H)**
786 CXCR3+ CCR6-(Th1), **(I)** CXCR3- CCR6- (Th2), **(J)** CXCR3- CCR6+ (Th17), and **(K)** CXCR5+ CD4+ T cells within antigen specific
787 (AIM+) T cells in HIV+ volunteers. Comparison of two timepoints within the same group was done by Wilcoxon matched pair sign
788 ranked test. Comparison of two groups was done by two-tailed Mann-Whitney U test. Where indicated * = <0.05, ** = <0.01, *** = <
789 0.001 and **** = <0.000.

Figure 5: Responses to VOCs are preserved at 6 months post ChAdOx1 nCoV-19 vaccination in PWH




790
791
792
793
794
795
796
797
798
799

Figure 5: Responses to VOCs are preserved at 6 months post ChAdOx1 nCoV-19 vaccination in PWH.

(A) ACE-2 binding inhibition assay for alpha, beta and gamma VOCs measured at day 0 (baseline) and at day 182 (6 months post-vaccination) in HIV+ volunteers. (B) Comparison between ACE-2 binding inhibition of SARS-CoV-2 WT strain and alpha, beta and gamma VOCs in HIV+ volunteers. Comparison between proliferative T cell responses to SARS-CoV-2 WT strain and beta, gamma and delta VOCs in (C) CD4+ S1, (D) CD4+ S2, (E) CD8+ S1 and (F) CD8+ S2 in HIV+ volunteers. Comparative analysis of (G) CD4+ S1, (H) CD4+ S2, (I) CD8+ S1, and (J) CD8+ S2 T cells responses to VOCs in HIV+ (solid circles) and HIV- (open circles). Comparison of two timepoints within the same group was done by Wilcoxon matched pair sign ranked test. Comparison of two groups was done by two-tailed Mann-Whitney U test. Where indicated * = <0.05, ** = <0.01, *** = < 0.001 and **** = <0.000. Dotted lines in C- J indicate threshold for true positive based mean of DMSO controls + 3x SD.

Figure 6: Pre-existing cross-reactive CD4+ T cell responses in PWH measured at baseline are associated with high magnitude T cell responses post ChAdOx1 nCoV-19 vaccination




801
802

Figure 6: Pre-existing cross-reactive CD4+ T cell responses in PWH measured at baseline are associated with high magnitude T cell responses post ChAdOx1 nCoV-19 vaccination.

Baseline CD4+ SARS-CoV-2 responses were split into baseline responders (BR, proliferation >1%, black circles and black lines) and baseline non-responders (B-NR, Proliferation <1%, yellow circles and yellow lines) and CD4 T cell responses post vaccination were analysed at all available timepoints for (A) SARS-CoV-2 S1 and (B) SARS-CoV-2 S2. T cells responses targeting (C) S1 and (D) S2 proteins in endemic CCCs are measured at baseline in BR and B-NR. Comparison of two timepoints within the same group was done by Wilcoxon matched pair sign ranked test. Comparison of two groups was done by two-tailed multiple Mann-Whitney U test. CCC responses among participants were compared using fisher's exact test and listed in supplementary table 3. P values as indicated or * = <math><0.05</math>, ** = <math><0.01</math>, *** = <math><0.001</math> and **** = <math><0.0001</math>. Dotted lines in indicate threshold for true positive based mean of DMSO controls + 3x SD

812

Figure 7: Cross reactive humoral immune responses among betaCoVs



813
 814
 815
 816
 817
 818
 819
 820
 821

Figure 7: Cross reactive humoral immune responses among betaCoVs.

Antibody titres against (A) SARS-CoV, (B) MERS-CoV, and (C) HKU-1 spike proteins measured at day 0 (baseline) and day 182 (6 months post-vaccination) in HIV+ participants. Correlation between baseline antibody titres for SARS-CoV-2 and (D) SARS-CoV-1, (E) MERS-CoV, and (F) HKU-1 spike protein at baseline. (G) Phylogenetic tree showing relationship between coronaviruses. Correlation was performed via Spearman's rank correlation coefficient and comparison of two timepoints within the same group was done by Wilcoxon matched pair sign ranked test. Where indicated ns = not significant, * = <0.05, ** = <0.01, *** = < 0.001 and **** = <0.0001. Dotted lines in A – B indicate cut off points determined for each SARS-CoV-2 antigen based on pre-pandemic sera + 3X SD.

822 **Supplementary figure legends**

823

824 **Supplementary figure 1: Flow cytometry gating strategy and kinetics of cells** 825 **expressing activation and exhaustion marker.**

826 Gating strategy for (A) activation panel and (B) exhaustion panel. All gates were set
827 based on fluorescent minus one (FMO). Frequency of cells expressing (C) CD38+
828 HLA DR+, (D) PD-1+, (E) Eomes(hi) Tbet(lo) within CD4+ T cells on HIV+ participants
829 and frequency of cells expressing (F) CD38+ HLA DR+, (G) PD-1+, (H) Eomes(hi)
830 Tbet(lo) within CD8+ T cells on HIV+ participants. Frequency of cells expressing (I)
831 CD38+ HLA DR+, (J) PD-1+, (K) Eomes(hi) Tbet(lo) within CD4+ T cells on HIV-
832 participants and frequency of cells expressing (L) CD38+ HLA DR+, (M) PD-1+, (N)
833 Eomes(hi) Tbet(lo) within CD8+ T cells on HIV- participants. Comparison of two
834 timepoints within the same group was done by Wilcoxon matched pair sign ranked
835 test. Where indicated * = <0.05, ** = <0.01, *** = < 0.001 and **** = <0.0001

836

837

838 **Supplementary figure 2: Humoral immune responses against SARS-CoV-2 in** 839 **PWH.**

840 (A) Correlations between antibody levels measured using MSD assay and in-house
841 total IgG ELISA at (A) day 0, (B) day 182 and (C) correlations between day 182 SARS-
842 CoV-2 RBD levels and ACE-2 binding inhibition assay. (D) Antibody levels in HIV+
843 participants measured across all timepoints presented as dot plots and, (E) before-
844 after plots to show individual responses. (F) Correlation plot showing correlation matrix
845 between SARS-CoV-2 humoral immune response across all proteins, assays and
846 timepoints. Correlation was performed via Spearman's rank correlation coefficient and
847 correlation matrix was created using corrplot package on R studio. Size and Colour of
848 the heatmap corresponds to the correlation coefficient. Comparison of two timepoints
849 within the same group was done by Wilcoxon matched pair sign ranked test. Where
850 indicated * = <0.05, ** = <0.01, *** = < 0.001 and **** = <0.0001.

851

852

853 **Supplementary figure 3: Gating strategy and T cell response to control antigens** 854 **(FECT) and mitogen (PHA).**

855 (A) Gating strategy for proliferation assay. All gates were set based on DMSO controls.
856 Background was subtracted and responses were assigned positive if they were >1%
857 after background subtraction. (B) PHA responses in CD4+ and CD8+ T cells at
858 longitudinal timepoints. (C) FECT responses in CD4+ and CD8+ T cells at longitudinal
859 timepoints. Comparison of two timepoints within the same group was done by
860 Wilcoxon matched pair sign ranked test. Where indicated * = <0.05, ** = <0.01, *** =
861 < 0.001 and **** = <0.000. Dotted lines in indicate threshold for true positive based
862 mean of DMSO controls + 3x SD.

863

864

865

866 **Supplementary figure 4: Longitudinal T cell responses to SARS-CoV-2 in HIV+** 867 **and HIV- subjects following ChAdOx1 nCoV-19 vaccination.**

868 (A) IFN γ ELISpot responses in HIV- volunteers at day 0, 42 and 182. T cell proliferative
869 response to (B) SARS-CoV-2 S1, (C) SARS-CoV-2 S2 in CD4+ T cells in HIV-
870 volunteers and T cell proliferative response to (D) SARS-CoV-2 S1, (E) SARS-CoV-2
871 S2 in CD8+ T cells in HIV- volunteers. Comparison of T cell proliferative responses to

872 **(F)** SARS-CoV-2 S1, **(G)** SARS-CoV-2 S2 in CD4+ T cells **(H)** SARS-CoV-2 S1, **(I)**
873 SARS-CoV-2 S2 in CD8+ T cells in HIV+ and HIV negative volunteers at day 0, 42
874 and 182. Comparison of two timepoints within the same group was done by Wilcoxon
875 matched pair sign ranked test. Comparison of two groups was done by two-tailed
876 multiple Mann-Whitney U test. Where indicated * = <0.05, ** = <0.01, *** = < 0.001
877 and **** = <0.000. Dotted lines in indicate threshold for true positive based mean of
878 DMSO controls + 3x SD.

879
880

881 **Supplementary figure 5: Phenotype of total and SARS-CoV-2 S-specific**
882 **circulating CD4+ T cells**

883 **(A)** *Ex vivo* frequencies of **(A)** CXCR3+ CCR6+ (Th1), CXCR3- CCR6- (Th2), CXCR3-
884 CCR6+ (Th17), and CXCR5+ within CD4+ T cells in HIV- volunteers measured at
885 various timepoints. **(B)** gating strategy for AIM assay. All cells expressing CD25+
886 CD134 (OX40) and CD25+ CD137+ and CD25+ CD69+ were Boolean gated as
887 antigen specific cells. Gating was set based on DMSO control and all responses were
888 background subtracted. CXCR3 and CCR6 quadrant gate for antigen specific
889 population was set based on expression in bulk CD4 T cell population. **(C)** Frequency
890 of CD4 T cell subsets in SEB, SARS-CoV-2 S1, SARS-CoV-2 S2, HIV GAG and
891 CMVpp65. Comparison of two timepoints within the same group was done by
892 Wilcoxon matched pair sign ranked test. Comparison of two groups was done by two-
893 tailed multiple Mann-Whitney U test. Where indicated * = <0.05, ** = <0.01, *** = <
894 0.001 and **** = <0.000.

895
896

897 **Supplementary figure 6: Pre-existing cross-reactive immunity in PWH measured**
898 **at baseline are associated with high magnitude CD8+ T cell responses post**
899 **ChAdOx1 nCoV-19 vaccination**

900 Baseline CD8+ SARS-CoV-2 responses were split into baseline responders (BR,
901 proliferation >1%, black circles and black lines) and baseline non-responders (B-NR,
902 Proliferation <1%, yellow circles and yellow lines) and CD8 T cell responses post
903 vaccination were analysed at all available timepoints for **(A)** SARS-CoV-2 S1 and **(B)**
904 SARS-CoV-2 S2. T cells responses targeting **(C)** S1 and **(D)** S2 proteins in endemic
905 CCCs are measured at baseline in BR and B-NR. Comparison of two timepoints within
906 the same group was done by Wilcoxon matched pair sign ranked test. Comparison of
907 two groups was done by two-tailed multiple Mann-Whitney U test. CCC responses
908 among participants were compared using fisher's exact test and listed in
909 supplementary table 3. P values as indicated or * = <0.05, ** = <0.01, *** = < 0.001
910 and **** = <0.000. Dotted lines in indicate threshold for true positive based mean of
911 DMSO controls + 3x SD.

912
913

914 **Supplementary figure 7: Relationship between baseline and post vaccination.**
915 **timepoints for CD4+ and CD8+ proliferative T cells.**

916 Correlation plots showing correlation matrix for **(A)** CD4+ SARS-CoV-2 S1, **(B)** CD4+
917 SARS-CoV-2 S2, **(C)** CD8+ SARS-CoV-2 S1, **(D)** CD8+ SARS-CoV-2 S2. Correlation
918 was performed via Spearman's rank correlation coefficient and correlation matrix was
919 created using corrplot package on R studio. Size and Colour of the heatmap
920 corresponds to the correlation coefficient. Where indicated * = <0.05, ** = <0.01, *** =
921 < 0.001 and **** = <0.0001.

922 **Supplementary figure 8: Responses to CCC in PWH**

923 T cell proliferative responses to CCCs HKU-1 clade 1 and 2, OC43, 299E, NL63 S1
924 and S2 in CD4+ and CD8+ T cells measured on day 0, 14, 28, 42, 56 and 182.
925 Comparison of two timepoints within the same group was done by Wilcoxon matched
926 pair sign ranked test. P values as indicated or * = <0.05, ** = <0.01, *** = < 0.001 and
927 **** = <0.000. Dotted lines in indicate threshold for true positive based mean of DMSO
928 controls + 3x SD.

929

930

931 **Supplementary figure 9: Relationship between antibody responses for SARS-**
932 **CoV-2 and CCCs spike in PWH**

933 **(A)** Correlation plot showing correlation matrix between different circulating HCoVs.

934 **(B)** Antibody titres at day 0 and day 182 for OC43 Spike, 299E spike and NL63 spike
935 proteins in HIV+ participants. Correlation was performed via Spearman's rank
936 correlation coefficient and correlation matrix was created using corrplot package on R
937 studio. Size and Colour of the heatmap corresponds to the correlation coefficient.

938 Comparison of two timepoints within the same group was done by Wilcoxon matched
939 pair sign ranked test. Where indicated * = <0.05, ** = <0.01, *** = < 0.001 and **** =
940 <0.0001.

941 **References**

- 942 1. WHO. WHO Coronavirus (COVID-19) Dashboard. In: World Health Organization;
943 2021.
- 944 2. Mellor MM, Bast AC, Jones NR, Roberts NW, Ordóñez-Mena JM, Reith AJM, Butler
945 CC, et al. Risk of adverse coronavirus disease 2019 outcomes for people living with HIV. *AIDS*
946 (London, England) 2021;35:F1-F10.
- 947 3. Sheth AN, Althoff KN, Brooks JT. Influenza susceptibility, severity, and shedding in
948 HIV-infected adults: a review of the literature. *Clinical infectious diseases : an official*
949 *publication of the Infectious Diseases Society of America* 2011;52:219-227.
- 950 4. Abadom TR, Smith AD, Tempia S, Madhi SA, Cohen C, Cohen AL. Risk factors
951 associated with hospitalisation for influenza-associated severe acute respiratory illness in
952 South Africa: A case-population study. *Vaccine* 2016;34:5649-5655.
- 953 5. Tesoriero JM, Swain CE, Pierce JL, Zamboni L, Wu M, Holtgrave DR, Gonzalez CJ, et al.
954 COVID-19 Outcomes Among Persons Living With or Without Diagnosed HIV Infection in New
955 York State. *JAMA Netw Open* 2021;4:e2037069.
- 956 6. Geretti AM, Stockdale AJ, Kelly SH, Cevik M, Collins S, Waters L, Villa G, et al.
957 Outcomes of COVID-19 related hospitalization among people with HIV in the ISARIC WHO
958 Clinical Characterization Protocol (UK): a prospective observational study. *Clin Infect Dis*
959 2020.
- 960 7. Martin GE, Sen DR, Pace M, Robinson N, Meyerowitz J, Adland E, Thornhill JP, et al.
961 Epigenetic Features of HIV-Induced T-Cell Exhaustion Persist Despite Early Antiretroviral
962 Therapy. *Frontiers in Immunology* 2021;12:1458.
- 963 8. BHIVA. BHIVA guidelines on the use of vaccines in HIV-positive adults 2015. In.
964 www.bhiva.org/vaccination-guidelines; 2021.
- 965 9. Kroon FP, van Dissel JT, de Jong JC, van Furth R. Antibody response to influenza,
966 tetanus and pneumococcal vaccines in HIV-seropositive individuals in relation to the
967 number of CD4+ lymphocytes. *AIDS (London, England)* 1994;8:469-476.
- 968 10. Cole ME, Saeed Z, Shaw AT, Guo Y, Höschler K, Winston A, Cooke GS, et al.
969 Responses to Quadrivalent Influenza Vaccine Reveal Distinct Circulating CD4+CXCR5+ T Cell
970 Subsets in Men Living with HIV. *Scientific Reports* 2019;9:15650.
- 971 11. Zanetti AR, Amendola A, Besana S, Boschini A, Tanzi E. Safety and immunogenicity of
972 influenza vaccination in individuals infected with HIV. *Vaccine* 2002;20:B29-B32.
- 973 12. Bridges CB, Fukuda K, Cox NJ, Singleton JA. Prevention and control of influenza.
974 Recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR*
975 *Recomm Rep* 2001;50:1-44.
- 976 13. Christensen-Quick A, Chaillon A, Yek C, Zanini F, Jordan P, Ignacio C, Caballero G, et
977 al. Influenza Vaccination Can Broadly Activate the HIV Reservoir During Antiretroviral
978 Therapy. *Journal of acquired immune deficiency syndromes (1999)* 2018;79:e104-e107.
- 979 14. Yek C, Gianella S, Plana M, Castro P, Scheffler K, García F, Massanella M, et al.
980 Standard vaccines increase HIV-1 transcription during antiretroviral therapy. *AIDS (London,*
981 *England)* 2016;30:2289-2298.
- 982 15. Ramasamy MN, Minassian AM, Ewer KJ, Flaxman AL, Folegatti PM, Owens DR,
983 Voysey M, et al. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a
984 prime-boost regimen in young and old adults (COV002): a single-blind, randomised,
985 controlled, phase 2/3 trial. *The Lancet* 2020;396:1979-1993.

- 986 16. Frater J, Ewer KJ, Ogbe A, Pace M, Adele S, Adland E, Alagaratnam J, et al. Safety and
987 immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV
988 infection: a single-arm substudy of a phase 2/3 clinical trial. *The Lancet HIV* 2021.
989 17. Folegatti PM, Ewer KJ, Aley PK, Angus B, Becker S, Belij-Rammerstorfer S, Bellamy D,
990 et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a
991 preliminary report of a phase 1/2, single-blind, randomised controlled trial. *The Lancet*
992 2020;396:467-478.
993 18. Ewer KJ, Barrett JR, Belij-Rammerstorfer S, Sharpe H, Makinson R, Morter R, Flaxman
994 A, et al. T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19
995 (AZD1222) vaccine in a phase 1/2 clinical trial. *Nature Medicine* 2021;27:270-278.
996 19. Adriana T, Donal TS, Ane O, Daniel O, Connor*, Matthew P, Emily A, et al. Divergent
997 trajectories of antiviral memory after SARS-Cov-2 infection. *Research Square* 2021.
998 20. Widge AT, Roupheal NG, Jackson LA, Anderson EJ, Roberts PC, Makhene M, Chappell
999 JD, et al. Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination. *New England*
1000 *Journal of Medicine* 2020;384:80-82.
1001 21. Mateus J, Dan JM, Zhang Z, Moderbacher CR, Lammers M, Goodwin B, Sette A, et al.
1002 Low dose mRNA-1273 COVID-19 vaccine generates durable T cell memory and antibodies
1003 enhanced by pre-existing crossreactive T cell memory. *medRxiv*
1004 2021:2021.2006.2030.21259787.
1005 22. Pegu A, O'Connell S, Schmidt SD, O'Dell S, Talana CA, Lai L, Albert J, et al. Durability
1006 of mRNA-1273 vaccine-induced antibodies against SARS-CoV-2 variants. *Science*
1007 2021:eabj4176.
1008 23. EpiFlu G. Tracking of Variants. In: *GISAID EpiFlu*; 2021.
1009 24. Lopez Bernal J, Andrews N, Gower C, Gallagher E, Simmons R, Thelwall S, Stowe J, et
1010 al. Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. *New England*
1011 *Journal of Medicine* 2021.
1012 25. England PH. SARS-CoV-2 variants of concern and variants under investigation in
1013 England Technical briefing 15. In: *PUBLIC HEALTH ENGLAND UK*; 2021.
1014 26. Nasreen S, Chung H, He S, Brown KA, Gubbay JB, Buchan SA, Fell DB, et al.
1015 Effectiveness of COVID-19 vaccines against variants of concern in Ontario, Canada. *medRxiv*
1016 2021:2021.2006.2028.21259420.
1017 27. Bergwerk M, Gonen T, Lustig Y, Amit S, Lipsitch M, Cohen C, Mandelboim M, et al.
1018 Covid-19 Breakthrough Infections in Vaccinated Health Care Workers. *New England Journal*
1019 *of Medicine* 2021.
1020 28. Mateus J, Grifoni A, Tarke A, Sidney J, Ramirez SI, Dan JM, Burger ZC, et al. Selective
1021 and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans. *Science* 2020;370:89.
1022 29. Grifoni A, Weiskopf D, Ramirez SI, Mateus J, Dan JM, Moderbacher CR, Rawlings SA,
1023 et al. Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19
1024 Disease and Unexposed Individuals. *Cell* 2020;181:1489-1501.e1415.
1025 30. Braun J, Loyal L, Frentsch M, Wendisch D, Georg P, Kurth F, Hippenstiel S, et al. SARS-
1026 CoV-2-reactive T cells in healthy donors and patients with COVID-19. *Nature* 2020;587:270-
1027 274.
1028 31. Swadling L, Diniz MO, Schmidt NM, Amin OE, Chandran A, Shaw E, Pade C, et al. Pre-
1029 existing polymerase-specific T cells expand in abortive seronegative SARS-CoV-2 infection.
1030 *medRxiv* 2021:2021.2006.2026.21259239.

- 1031 32. Le Bert N, Tan AT, Kunasegaran K, Tham CYL, Hafezi M, Chia A, Chng MHY, et al.
1032 SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected
1033 controls. *Nature* 2020;584:457-462.
- 1034 33. Ng KW, Faulkner N, Cornish GH, Rosa A, Harvey R, Hussain S, Ulferts R, et al.
1035 Preexisting and de novo humoral immunity to SARS-CoV-2 in humans. *Science*
1036 2020;370:1339.
- 1037 34. Ogbe A, Kronsteiner B, Skelly DT, Pace M, Brown A, Adland E, Adair K, et al. T cell
1038 assays differentiate clinical and subclinical SARS-CoV-2 infections from cross-reactive
1039 antiviral responses. *Nature Communications* 2021;12:2055.
- 1040 35. Loyal L, Braun J, Henze L, Kruse B, Dingeldej M, Reimer U, Kern F, et al. Cross-
1041 reactive CD4+ T cells enhance SARS-CoV-2 immune responses upon infection and
1042 vaccination. *medRxiv* 2021:2021.2004.2001.21252379.
- 1043 36. Shrock E, Fujimura E, Kula T, Timms RT, Lee IH, Leng Y, Robinson ML, et al. Viral
1044 epitope profiling of COVID-19 patients reveals cross-reactivity and correlates of severity.
1045 *Science* 2020;370:eabd4250.
- 1046 37. Poston D, Weisblum Y, Wise H, Templeton K, Jenks S, Hatzioannou T, Bieniasz P.
1047 Absence of SARS-CoV-2 neutralizing activity in pre-pandemic sera from individuals with
1048 recent seasonal coronavirus infection. *Clin Infect Dis* 2020.
- 1049 38. Anderson EM, Goodwin EC, Verma A, Arevalo CP, Bolton MJ, Weirick ME, Gouma S,
1050 et al. Seasonal human coronavirus antibodies are boosted upon SARS-CoV-2 infection but
1051 not associated with protection. *Cell* 2021;184:1858-1864.e1810.
- 1052 39. McNaughton AL, Paton RS, Edmans M, Youngs J, Wellens J, Phalora P, Fyfe A, et al.
1053 Fatal COVID-19 outcomes are associated with an antibody response targeting epitopes
1054 shared with endemic coronaviruses. *medRxiv* 2021:2021.2005.2004.21256571.
- 1055 40. Hileman CO, Funderburg NT. Inflammation, Immune Activation, and Antiretroviral
1056 Therapy in HIV. *Current HIV/AIDS Reports* 2017;14:93-100.
- 1057 41. Madhi SA, Koen AL, Izu A, Fairlie L, Cutland CL, Baillie V, Padayachee SD, et al. Safety
1058 and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in
1059 people living with and without HIV in South Africa: an interim analysis of a randomised,
1060 double-blind, placebo-controlled, phase 1B/2A trial. *The Lancet HIV* 2021;8:e568-e580.
- 1061 42. Kunisaki KM, Janoff EN. Influenza in immunosuppressed populations: a review of
1062 infection frequency, morbidity, mortality, and vaccine responses. *The Lancet Infectious*
1063 *Diseases* 2009;9:493-504.
- 1064 43. Golding B, Scott DE. Vaccine strategies: targeting helper T cell responses.
- 1065 44. Nielsen CM, Ogbe A, Pedroza-Pacheco I, Doeleman SE, Chen Y, Silk SE, Barrett JR, et
1066 al. Protein/AS01B vaccination elicits stronger, more Th2-skewed antigen-specific human T
1067 follicular helper cell responses than heterologous viral vectors. *Cell Reports Medicine*
1068 2021;2:100207.
- 1069 45. Taylor JM, Ziman ME, Canfield DR, Vajdy M, Solnick JV. Effects of a Th1- versus a Th2-
1070 biased immune response in protection against *Helicobacter pylori* challenge in mice.
1071 *Microbial pathogenesis* 2008;44:20-27.
- 1072 46. Bowyer G, Grobbelaar A, Rampling T, Venkatraman N, Morelle D, Ballou RW, Hill
1073 AVS, et al. CXCR3+ T Follicular Helper Cells Induced by Co-Administration of RTS,S/AS01B
1074 and Viral-Vectored Vaccines Are Associated With Reduced Immunogenicity and Efficacy
1075 Against Malaria. *Frontiers in Immunology* 2018;9.

- 1076 47. Bentebibel S-E, Khurana S, Schmitt N, Kurup P, Mueller C, Obermoser G, Palucka AK,
1077 et al. ICOS+PD-1+CXCR3+ T follicular helper cells contribute to the generation of high-avidity
1078 antibodies following influenza vaccination. *Scientific Reports* 2016;6:26494.
- 1079 48. Rodda LB, Netland J, Shehata L, Pruner KB, Morawski PA, Thouvenel CD, Takehara
1080 KK, et al. Functional SARS-CoV-2-Specific Immune Memory Persists after Mild COVID-19. *Cell*
1081 2021;184:169-183.e117.
- 1082 49. Rydyznski Moderbacher C, Ramirez SI, Dan JM, Grifoni A, Hastie KM, Weiskopf D,
1083 Belanger S, et al. Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and
1084 Associations with Age and Disease Severity. *Cell* 2020;183:996-1012.e1019.
- 1085 50. Juno JA, Tan H-X, Lee WS, Reynaldi A, Kelly HG, Wragg K, Esterbauer R, et al.
1086 Humoral and circulating follicular helper T cell responses in recovered patients with COVID-
1087 19. *Nature Medicine* 2020;26:1428-1434.
- 1088 51. Zhou R, To KK-W, Wong Y-C, Liu L, Zhou B, Li X, Huang H, et al. Acute SARS-CoV-2
1089 Infection Impairs Dendritic Cell and T Cell Responses. *Immunity* 2020;53:864-877.e865.
- 1090 52. Dan JM, Mateus J, Kato Y, Hastie KM, Yu ED, Faliti CE, Grifoni A, et al. Immunological
1091 memory to SARS-CoV-2 assessed for up to 8 months after infection. *Science*
1092 2021;371:eabf4063.
- 1093 53. Tso FY, Lidenge SJ, Poppe LK, Peña PB, Privatt SR, Bennett SJ, Ngowi JR, et al.
1094 Presence of antibody-dependent cellular cytotoxicity (ADCC) against SARS-CoV-2 in COVID-
1095 19 plasma. *PLOS ONE* 2021;16:e0247640.
- 1096 54. Lee WS, Selva KJ, Davis SK, Wines BD, Reynaldi A, Esterbauer R, Kelly HG, et al. Decay
1097 of Fc-dependent antibody functions after mild to moderate COVID-19. *Cell Reports*
1098 *Medicine* 2021;2:100296.
- 1099 55. Chen X, Rostad CA, Anderson LJ, Sun H-y, Lapp SA, Stephens K, Hussaini L, et al. The
1100 development and kinetics of functional antibody-dependent cell-mediated cytotoxicity
1101 (ADCC) to SARS-CoV-2 spike protein. *Virology* 2021;559:1-9.
- 1102 56. Alrubayyi A, Gea-Mallorquí E, Touizer E, Hameiri-Bowen D, Kopycinski J, Charlton B,
1103 Fisher-Pearson N, et al. Characterization of humoral and SARS-CoV-2 specific T cell
1104 responses in people living with HIV. *bioRxiv* 2021:2021.2002.2015.431215.
- 1105 57. Wajnberg A, Amanat F, Firpo A, Altman DR, Bailey MJ, Mansour M, McMahon M, et
1106 al. Robust neutralizing antibodies to SARS-CoV-2 infection persist for months. *Science*
1107 2020;370:1227.
- 1108 58. Geers D, Shamier MC, Bogers S, den Hartog G, Gommers L, Nieuwkoop NN, Schmitz
1109 KS, et al. SARS-CoV-2 variants of concern partially escape humoral but not T cell responses
1110 in COVID-19 convalescent donors and vaccine recipients. *Science Immunology*
1111 2021;6:eabj1750.
- 1112 59. Liu Y, Liu J, Xia H, Zhang X, Fontes-Garfias CR, Swanson KA, Cai H, et al. Neutralizing
1113 Activity of BNT162b2-Elicited Serum. *New England Journal of Medicine* 2021;384:1466-
1114 1468.
- 1115 60. Wang P, Nair MS, Liu L, Iketani S, Luo Y, Guo Y, Wang M, et al. Antibody resistance of
1116 SARS-CoV-2 variants B.1.351 and B.1.1.7. *Nature* 2021;593:130-135.
- 1117 61. Shrock E, Fujimura E, Kula T, Timms RT, Lee IH, Leng Y, Robinson ML, et al. Viral
1118 epitope profiling of COVID-19 patients reveals cross-reactivity and correlates of severity.
1119 *Science* 2020;370:eabd4250.
- 1120 62. Supasa P, Zhou D, Dejnirattisai W, Liu C, Mentzer AJ, Ginn HM, Zhao Y, et al. Reduced
1121 neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera. *Cell*
1122 2021;184:2201-2211.e2207.

1123